Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Share-based Compensation (2019 - 2025)

Cyclerion Therapeutics (CYCN) has disclosed Share-based Compensation for 7 consecutive years, with $118000.0 as the latest value for Q3 2025.

  • For Q3 2025, Share-based Compensation fell 14.49% year-over-year to $118000.0; the TTM value through Sep 2025 reached $468000.0, down 22.77%, while the annual FY2024 figure was $625000.0, 41.42% down from the prior year.
  • Share-based Compensation hit $118000.0 in Q3 2025 for Cyclerion Therapeutics, up from $114000.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $2.5 million in Q4 2021 and bottomed at $103000.0 in Q4 2023.
  • Average Share-based Compensation over 5 years is $942157.9, with a median of $379000.0 recorded in 2023.
  • Year-over-year, Share-based Compensation plummeted 90.84% in 2023 and then rose 18.45% in 2024.
  • Cyclerion Therapeutics' Share-based Compensation stood at $2.5 million in 2021, then tumbled by 55.87% to $1.1 million in 2022, then tumbled by 90.84% to $103000.0 in 2023, then grew by 18.45% to $122000.0 in 2024, then decreased by 3.28% to $118000.0 in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $118000.0, $114000.0, and $114000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.